EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) recently reported its financial and operational results for the first quarter ended March 31, 2022.
“We continue to preserve cash while actively pursuing new development or commercial-stage assets for Idera’s portfolio,” stated Vincent Milano, Idera’s Chief Executive Officer. “We also continue to work with JMP Securities, a Citizens Company, our current partner and advisor on business development activities, to explore additional strategic alternatives for the Company.”
First Quarter Financial Results
The Company’s cash position as of March 31, 2022, was $28.0 million. Based on its current operating plan, the Company anticipates that its current cash and cash equivalents will fund its operations through the one-year period subsequent to the May 5, 2022 filing date of the Quarterly Report Form 10-Q.
Research and development expenses for the three months ended March 31, 2022, totaled $1.8 million, compared to $6.9 million for the same period in 2021. General and administrative expense for the three months ended March 31, 2022, totaled $2.4 million, compared to $3.2 million for the same period in 2021.
Additionally, during the three months ended March 31, 2021, the Company recorded $7.0 million and $118.8 million non-cash warrant revaluation gain and non-cash future tranche right revaluation gain, respectively, related to the change in fair value of securities issued in connection with the Company’s December 2019 private placement transaction. No such non-cash gains were recognized in the three months ended March 31, 2022, as the warrants and future tranche rights were terminated in the first quarter of 2021.
As a result of the factors above, net loss applicable to common stockholders for the three months ended March 31, 2022, was $4.2 million or $0.08 per basic and diluted share compared to net income applicable to common stockholders of $109.6 million or $2.66 per basic share for 2021. On a diluted basis, net loss applicable to common stockholders for the three months ended March 31, 2021, was $10.0 million or $0.14 per diluted share.
Excluding the non-cash gain of approximately $125.8 million for the three months ended March 31, 2021, related to the termination of securities issued in connection with the December 2019 private placement transaction, net loss applicable to common stockholders was $10.0 million, or $0.24 per basic and diluted share (calculated based upon the basic weighted-average number of common shares, due to the antidilutive effect of net loss).
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.